Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1001 ECP Emmecell
BioCentury & Getty Images

Emerging Company Profile

Emmecell: magnetic cell therapy for eye diseases

Emmecell is slated to begin Phase I testing in corneal edema patients next year

Emmecell uses its magnetic nanoparticle platform to improve cell delivery, retention and integration in ophthalmic indications. 

Oct 3, 2020 | 3:24 AM GMT

Emmecell emerged from stealth last week with a clinic-ready cell therapy for corneal edema that could address mild disease and offer a less invasive alternative

Read the full 739 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers